z-logo
open-access-imgOpen Access
Comparing treatment strategies to reduce antibiotic resistance in an in vitro epidemiological setting
Author(s) -
Daniel C Angst,
Burcu Tepekule,
Lei Sun,
Balázs Bogos,
Sebastian Bonhoeffer
Publication year - 2021
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2023467118
Subject(s) - context (archaeology) , epidemiology , antibiotic resistance , population , antibiotics , intensive care medicine , resistance (ecology) , medicine , risk analysis (engineering) , computer science , biology , environmental health , microbiology and biotechnology , ecology , paleontology
The rapid rise of antibiotic resistance, combined with the increasing cost and difficulties to develop new antibiotics, calls for treatment strategies that enable more sustainable antibiotic use. The development of such strategies, however, is impeded by the lack of suitable experimental approaches that allow testing their effects under realistic epidemiological conditions. Here, we present an approach to compare the effect of alternative multidrug treatment strategies in vitro using a robotic liquid-handling platform. We use this framework to study resistance evolution and spread implementing epidemiological population dynamics for treatment, transmission, and patient admission and discharge, as may be observed in hospitals. We perform massively parallel experimental evolution over up to 40 d and complement this with a computational model to infer the underlying population-dynamical parameters. We find that in our study, combination therapy outperforms monotherapies, as well as cycling and mixing, in minimizing resistance evolution and maximizing uninfecteds, as long as there is no influx of double resistance into the focal treated community.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here